Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 732 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Disease, Eczematous Skin Clear all
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

NCT03131648
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Novel Topical Treatment of Hand Dermatitis (Eczema)

NCT00614289
View directory record Official record
Conditions
Contact Dermatitis, Eczema, Contact
Interventions
Epikeia Coatings
Device
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2010 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis

NCT01712360
View directory record Official record
Conditions
Tinea Pedis, Tinea Cruris
Interventions
NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult), NAFT600 (adult)
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Austin, Texas • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jun 10, 2026, 2:08 PM EDT
Completed No phase listed Observational

A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)

NCT05235724
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Montgomery, Alabama • Hialeah, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

NCT03431610
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
SB414 2%, SB414 6%, Vehicle
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jun 10, 2026, 2:08 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT03831191
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LY3375880, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Northridge, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

NCT03945760
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Wright State Physicians
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

NCT00403559
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Elidel, Ketoconazole Cream
Drug
Lead sponsor
Dermatology Specialists Research
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Jun 10, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

NCT00275795
View directory record Official record
Conditions
Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions
NAET Procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
2 Years to 78 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2006 · Synced Jun 10, 2026, 2:08 PM EDT
Recruiting No phase listed Observational

Registry for Systemic Eczema Treatments

NCT06136767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 26 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

NCT04973228
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam, Vehicle Foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
9 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • San Diego, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jun 10, 2026, 2:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

NCT00879944
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
Blood pressure, Height, Weight, BMI, Waist Circumference
Other
Lead sponsor
Northwestern University
Other
Eligibility
5 Years to 17 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
9
States / cities
San Diego, California • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 3 Interventional Results available

Comparing Tissue Adhesives in Port Site Closure

NCT05492721
View directory record Official record
Conditions
Dermatitis, Contact
Interventions
Dermabond (2-Octylcyanoacrylate), Swiftset (N-butyl-2-cyanoacrylate), Liquiband (2-Octylcyanoacrylate)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Terminated Phase 4 Interventional

Tralokinumab for Dupilumab Failures

NCT06773455
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tralokinumab
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 1 Interventional

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT02647086
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Jun 10, 2026, 2:08 PM EDT
Terminated No phase listed Observational

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

NCT00911430
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06130566
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Results available

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

NCT04664153
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment, Vehicle ointment
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jun 10, 2026, 2:08 PM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis.

NCT01177566
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
pimecrolimus, topical medical device
Drug · Device
Lead sponsor
Emer, Jason, M.D.
Individual
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2010 · Synced Jun 10, 2026, 2:08 PM EDT
Terminated Phase 4 Interventional Results available

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

NCT05200403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
3 Months to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jun 10, 2026, 2:08 PM EDT
Recruiting Phase 2 Interventional

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

NCT07277660
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Galvokimig, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Oceanside, California • Santa Monica, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Recruiting Phase 2 Interventional

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
APG777
Drug
Lead sponsor
Apogee Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 2:08 PM EDT
Not listed No phase listed Observational

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

NCT05084417
View directory record Official record
Conditions
Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions
N/A This is an observational study
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Jun 10, 2026, 2:08 PM EDT